TABLE 5.

Recognition of preproinsulin peptides by PBMCs of diabetic patients: median values of stimulation score

P*	HLA	Responses†				Comparison‡
		L	R	C	D	Patients	Control subjects	P value
2–11	A2	3.3 (0–12.2)	10.0 (0–41.8)	0.56 (0–8.3)	0 (0–0)	7.8 (0–41.8)	0 (0–8.3)	0.01
	A24	5.2 (2.2–12.2)	0 (0–41.8)	—	—	2.8 (0–41.8)	—	—
	B8	25 (0–105)	8.2 (0–37.2)	0 (0–1.1)	0 (0–5.6)	15.6 (0–105)	0 (0–5.6)	0.01
6–16	A2	12.2 (10–54.5)	5 (0–111.7)	0 (0–9.5)	0 (0–0)	7.3 (0–111.7)	0 (0–9.5)	0.004
6–14	A2	28.9 (21.1–51.1)	30.6 (7.8–144)	4.7 (3.9–7.2)	—	30.6 (7.8–144)	4.7 (3.9–7.2)	0.01
14–23	A2	11.1 (7.8–12.2)	7.7 (54–0)	1.4 (0–5.6)	—	8.9 (54–0)	1.4 (0–5.6)	0.04
15–24	A2	12.8 (2.4–32.2)	8.7 (0–52.8)	0 (0–0)	—	12.2 (0–52.8)	0 (0–0)	0.002
15–25	A1	13.6 (6.1–25.6)	1.7 (0–14.4)	—	—	9.2 (0–25.6)	—	—
	A24	11.1 (5.8–25.6)	0 (0–14.4)	—	—	0 (0–25.6)	—	—

Data are median (range). P, peptide; R, recent-onset diabetes; L, long-standing diabetes; C, healthy control subjects; D, type 2 diabetic control subjects.

^*NH₂- and COOH-terminal amino acids in preproinsulin.

^†ELISpot responses; median (range) of stimulation score; stimulation score = mean number of spots in response to peptide − mean number of spots in absence of peptide.

^‡P values comparing the median responses in patients versus control subjects; nonparametric Mann-Whitney test.